Pharmaceuticals
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
SINGAPORE, Oct. 27, 2025 /PRNewswire/ -- Raffles Medical Group
2025-10-27 13:22
1327
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility
blends Pharma 4.0™ principles with sustainable design to transform plasma
manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL
2025-10-27 11:23
1932
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...
2025-10-27 09:51
1087
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...
2025-10-27 09:00
1435
Indonesia's Legacy in the Global Vaccine Landscape, Bio Farma and DCVMN Strengthen Health Resilience Through Global Partnership
BANDUNG, Indonesia, Oct. 25, 2025 /PRNewswire/ -- Through PT Bio Farma (Persero),Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's...
2025-10-25 18:52
2636
The Future of Life Sciences, Omics and AI Examined by Leading Global Genomic Experts
Groundbreaking Human-Centric Genomic Foundation Model Unveiled HANGZHOU, China, Oct. 24, 2025 /PRNewswire/ -- The future of Omics and AI in life sciences is the central theme for more than 100 scientists and guests from 19 countries and regions gathered inHangzhou, China, for the 20th Annual Mee...
2025-10-24 18:13
1209
Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infec...
2025-10-24 18:12
2285
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
* The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics inOctober 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNT...
2025-10-24 17:33
1352
/C O R R E C T I O N -- IFPA/
In the news release, World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis, issued23-Oct-2025 by IFPA over PR Newswire, we are advised by the company that the quotation byFrida Dunger, Executive Director of IFPA, should read "It's also time to move towards increased understa...
2025-10-24 05:15
1947
A New Era in Cervical Cancer Elimination: INNOVAX Presents Global Progress with HPV 9-Valent Vaccine on IPVS 2025 Opening Day
BANGKOK, Thailand, Oct. 23, 2025 /PRNewswire/ -- Xiamen Innovax Biotech Co., Ltd. ("INNOVAX") participated in the 37th International Papillomavirus Society (IPVS) Conference, and hosted a dedicated symposium titled "A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for ...
2025-10-23 23:24
1382
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (OD...
2025-10-23 20:15
870
FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
TAIPEI, Oct. 23, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy'...
2025-10-23 11:24
1304
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153 Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for t...
2025-10-23 04:00
1471
Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star inChina's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a$250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone ...
2025-10-22 23:39
1398
Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience
EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating th...
2025-10-22 18:00
1410
ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings from its ongoing Phase 1 study of ACM-CpG, a TLR9 agonist formulated with ACM's propriet...
2025-10-22 14:00
2005
ACROBiosystems and Partners Conclude OrganoAsia 2025
ACROBiosystems and Partners Conclude OrganoAsia 2025 - Leading Scientists from China, Japan and South Korea Convene to Drive Organoid Research and Commercialization TOKYO, Oct. 10, 2025 /PRNewswire/ -- ACROBiosystems, together with Leica Biosystems, Molecular Devices, and Leica Microsystem...
2025-10-22 11:03
2187
ACROBiosystems and Partners Conclude OrganoAsia 2025
In the news release, ACROBiosystems and Partners Conclude OrganoAsia 2025, issued10-Oct-2025 by ACROBiosystems Group over PR Newswire, "Tokyo University of Science" in the paragraph starting with "The conference gathered leading specialists such as..." should read "Institute of Science Tokyo"....
2025-10-22 11:01
2035
Abbott and BIG CARiNG Group Launch Nationwide Influenza Awareness Program to Strengthen Public Health Response Through Early Intervention
KUALA LUMPUR, Malaysia, Oct. 21, 2025 /PRNewswire/ -- Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one ofMalaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness acrossMalaysia. The Influenza Awareness Program, running ...
2025-10-21 13:12
1844
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...
2025-10-20 17:06
1334
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 304 media titles]
2026-01-27 13:00
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
